The eye diagnosis comes first
The National Eye Institute describes benefit for people with intermediate AMD in one or both eyes and some people with late AMD in one eye. An eye examination determines whether this evidence applies. Taking a product before establishing the diagnosis is not equivalent to the studied use. [1]
NEI states that the combination does not prevent early AMD from progressing to intermediate AMD. Continue ophthalmic follow-up rather than using a supplement as a substitute for it. [1]
The combination is not a single-vitamin result
The NEI formulation includes vitamins C and E, zinc, copper, lutein and zeaxanthin. An ordinary multivitamin or vitamin E capsule does not reproduce that intervention. Compare actual ingredients and amounts with the clinician’s recommended formula. [1]
Older AREDS formulations contain beta-carotene, which increases lung-cancer risk in people who smoke or previously smoked. AREDS2 omits beta-carotene. High nutrient amounts also make medication and duplicate-supplement review relevant. [1]
Similar packaging does not establish equivalence
Imagine two bottles both advertise eye health, but only one matches the recommended AREDS2 formula. The shared phrase does not establish the same evidence or suitability for the person’s AMD stage.
| Detail | Interpretation |
|---|---|
| AMD stage | Determines applicability |
| Full formula | The studied combination |
| Smoking history | Relevant to beta-carotene avoidance |
Sources for this article
- NEI: AREDS2 Supplements for Age-Related Macular Degeneration
Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product.